IFInês Furtado

Inês Furtado

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Inês Furtado has a total of 60 co-authors. Here are the top co-authors by number of shared publications:

  • Luísa Carvalho

    Internal Medicine Department; Pulmonary Vascular Disease Unit, Centro Hospitalar Universitario de Santo Antonio, Porto, Portugal

    3 shared publications
  • Mário Santos

    Department of Cardiology, Pulmonary Vascular Disease Unit, Unidade Local de Saúde de Santo António, Porto, Portugal; Department of Immuno-Physiology and Pharmacology, Unidade Multidisciplinar de Investigação Biomédica (UMIB), Instituto de Ciências Biomédicas Abel Salazar (ICBAS), Universidade do Porto, Porto, Portugal; ITR - Laboratory for Integrative and Translational Research in Population Health, Porto, Portugal

    3 shared publications
  • Abílio Reis

    Pulmonary Vascular Disease Unit, Centro Hospitalar Universitário de Santo António (CHUdSA) , Porto

    2 shared publications
  • Fabienne Gonçalves

    Pulmonary Vascular Disease Unit Centro Hospitalar Universitário do Porto Largo do Prof. Abel Salazar Porto Portugal

    2 shared publications
  • A. P. Santos

    Endocrinology Department, Instituto Português de Oncologia, Porto, Portugal

    1 shared publication
  • Abilio Reis

    PVD Unit, CHUP, Porto, Portugal

    1 shared publication

Latest Publications

  • Open Access

    From fibrosis to granuloma: drug induced systemic sarcoidosis-like reaction after rituximab in a patient with primary Sjögren’s syndrome

    by Rui Rua Coelho, Sara Xavier Pires, José Ricardo Brandão, Inês Furtado

    Sarcoidosis is a multisystemic syndrome characterized by non-caseous granulomatous inflammation, although necrotizing sarcoid granulomatosis is considered part of the spectrum of the disease. Drug induced sarcoidosis-like reaction (DISR) is a systemic granulomatous reaction, which is histopathologically identical to primary sarcoidosis - mostly described after the use of biologics like tumour necrosis factor alpha antagonists but also anti-CD20 (rituximab). The authors present the very rare case of a woman with a primary Sjögren’s syndrome (pSS) started on rituximab for disease control, which evolved with a 3-year indolent progressive systemic sarcoid reaction. There has been much speculation about the potential role of B cells in sarcoidosis. Findings show a decrease of B memory cells and an increase in naïve and active subsets of regulatory B cells in sarcoidosis patients, which resembles the repopulation with naïve B cells after treatment with rituximab. Moreover, granulomatous lymphocytic interstitial lung disease associated with common variable immunodeficiency and immune reconstitution syndrome in patients wirh human immunodeficiency virus show clinical similarities to DISR and can help unveil new cytogenic and physiologic pathways. To the authors’ knowledge this is the first report of a systemic sarcoidosis-like reaction with necrotizing granulomas following an anti-CD20 therapy and also the first described in a pSS patient - underlining the importance of recognizing necrotizing sarcoid granulomatous processes in the diferential diagnosis of patients with caseous inflammation. Although this is a very rare adverse effect, the case enhances the importance of actively searching for DISR after biologics, even in patients undergoing rescue on-label therapies, such as rituximab.


  • 10-year success story in CTEPH treatment: breaking the myth of rareness

    by Sofia Moura de Azevedo, Inês Furtado, Luísa Carvalho, Abílio Reis

    Unlike acute pulmonary embolism (PE), the resolution of thrombi is ineffective in chronic thromboembolic pulmonary hypertension (CTEPH), leading to reorganisation and fibrotic changes within the pulmonary arteries. The authors report the case of a man in his 60s with polycythemia vera, under warfarin, following an acute PE. He was admitted a year later with right heart failure and haemodynamic instability. Acute over chronic PE caused this severe presentation, confirmed by right heart catheterisation and pulmonary scintigraphy. The challenging diagnosis and management involved transfer to a centre specialised in pulmonary vascular disease. Normalisation of functional and haemodynamic parameters, sustained in 10-year follow-up, was achieved with anticoagulation and triple therapy with prostanoids as a bridge to pulmonary thromboendarterectomy. Targeted medical therapy, not standard at that time, was crucial to recovering conditions for transfer. An individualised approach, integrating multidisciplinary pulmonary hypertension expertise, provides the basis for the best care for CTEPH.


  • Open Access

    Transitioning Intravenous Epoprostenol to Oral Selexipag in Idiopathic Pulmonary Arterial Hypertension: A Case Report

    by André Alexandre, Inês Furtado, Luísa Carvalho, Fabienne Gonçalves, Alzira Melo, Joana Alves, Mário Santos, Abílio Reis

    Intravenous (i.v.) prostacyclin is the cornerstone treatment in high-risk pulmonary arterial hypertension (PAH) patients. Selexipag is an orally available prostacyclin receptor agonist. Limited data are available regarding the feasibility of transitioning from i.v. epoprostenol to selexipag. A 50-year-old woman with idiopathic PAH was diagnosed in a World Health Organization (WHO) Functional Class (FC) IV. She improved with upfront triple combination therapy, including i.v. epoprostenol. Over 2 years of follow-up, the patient remained at low risk and expressed strong preference towards oral therapies. After careful risk–benefit clinical consideration, she was transitioned from i.v. epoprostenol to selexipag. Selexipag was started at dosage of 200 μg twice daily (b.i.d.) and titrated up to 1600 μg b.i.d. over 8 weeks (up-titration of 200 μg b.i.d. every week). Simultaneously, i.v. epoprostenol was down-titrated 3.0 ng/kg/min every week from a dosage of 27.5 ng/kg/min. The transition occurred under strict medical surveillance and was well tolerated. One year after discontinuation of epoprostenol, the patient remains in WHO FC I and has no signs of clinical deterioration. Although not generalizable to most PAH patients, this case highlights that a carefully planned transition from epoprostenol to selexipag is feasible in selected low-risk patients within a shared medical decision-making framework.


  • External validation of different clinical and echocardiographic scores to distinguish post‐ from precapillary pulmonary hypertension

    by Maria Isilda Oliveira, Inês Furtado, Luísa Carvalho, Fabienne Gonçalves, Abílio Reis, Mário Santos

    Background: Even though right heart catheterization (RHC) is the gold‐standard method to characterise Pulmonary Hypertension (PH), it cannot be performed in all the patients with suspected PH. Clinical and echocardiographic scores have been developed to differentiate PH secondary to heart failure with preserved ejection fraction (PH‐HFpEF) from pre‐capillary PH. We aimed to compare the performance of non‐invasive parameters in a population with suspected PH.Methods: We retrospectively included consecutive patients who underwent RHC for suspected PH. Patients with a non‐invasive evaluation clearly suggestive of left heart disease were excluded. We assessed the performance of non‐invasive pulmonary vascular resistance (PVR), echocardiographic pulmonary to left atrial ratio (ePLAR), and Opotowsky, Richter, Berthelot, and D'Alto scores using the area under curve (AUC) of the receiver operating characteristic curves.Results: Of the 142 included patients, 61 patients had pre‐capillary PH, 49 had PH‐HFpEF, and 32 patients did not meet invasive criteria for PH. We were able to perform the aforementioned scores in 71–100% of our patients. Using the original cut‐offs, Opotowsky was the score that best predicted precapillary PH (96% sensitivity, 41% specificity, AUC .69), followed by D'Alto (98% sensitivity, 22% specificity, AUC .60) and Berthelot (32% sensitivity, 90% specificity, AUC .60). Richter score did not discriminate between phenotypes (AUC .50). Using optimised cut‐offs, a Berthelot score < 9 predicted precapillary PH with 73% sensitivity and 74% specificity (AUC .73). Single echocardiographic parameters as non‐invasive PVR (85% sensitivity, 59% specificity, AUC .72) and ePLAR (73% sensitivity, 76% specificity, AUC .75) showed better prediction performance than the composite studied scores.Conclusion: Combined clinical and echocardiographic characteristics can be used to predict pre‐capillary PH with moderate performance. The application of these non‐invasive parameters in clinical practice can help refine referral to RHC in a population with clinically suspected PH.


  • Pulmonary angioplasty vs exclusive medical treatment in inoperable chronic thromboembolic hypertension–initial outcomes from a pulmonary hypertension centre

    by Ines Furtado, Duarte Silva, Luisa Carvalho, Mario Santos, Fabienne Gonçalves, Andre Luz, Abilio Reis

    Background: Balloon pulmonary angioplasty (BPA) is a novel treatment modality in inoperable chronic thromboembolic hypertension (CTEPH) patients. Aims: Compare initial results of a BPA program in a Portuguese PH centre in inoperable CTEPH patients vs exclusive medical treatment (MT). Methods: This was a single centre, prospective study, from 01/2001 to 12/2019. CTEPH was diagnosed in 97 patients, with mean age of 67 years, 71% females. 25 patients who underwent PEA were excluded. From the remaining patients, 15 (group A) underwent BPA in addition to MT and 57 (group B) were under exclusive MT. Mean pulmonary artery pressure (mPAP), pulmonary vascular resistance (PVR), and cardiac index (CI) were measured at baseline, after at least 3 months of MT for group B and at each procedure for group A. Baseline and follow-up functional class (FC), 6-minute-walk-test (6MWT) and N-terminal brain natriuretic peptide (NT-BNP) were compared. A total of 36 BPA sessions were performed in group A. Results: In group A there was a statistically significant improvement after BPA of NT-proBNP (p=0.001), 6MWT (p<0,001), mPAP (p 0,016), PVR (p 0,01) and FC (p=0,034). There was no statistical significance in the aforementioned variables within group B. Between the two groups there was a significant improvement of hemodynamic variables, 6MWT and NT-proBNP favoring group A. There were no major complications in the patients submitted to BPA. Conclusions: BPA leads to significant improvement in clinical and hemodynamic parameters in inoperable CTEPH patients, representing a safe and seemingly effective treatment option.

  • Open Access

    São os Outcomes da Ventilação Não Invasiva na Falência Respiratória Aguda Similares nos Adultos Muito Idosos?

    by Ana Rita Costa, Inês Furtado, João Gonçalves, Mariana Meireles, João Neves, Andrea Mateus

    Introdução: Na população envelhecida, a falência respiratória aguda (FRA) é das causas mais prevalentes de observação no serviço de urgência. A ventilação não invasiva por pressão positiva (VNiPP) mostrou bons resultados nos doen- tes críticos com FRA. Mas a evidência em doentes muito idosos é escassa. O objetivo do estudo é analisar os outcomes do uso de VNiPP nesta população. Métodos: Conduzimos um estudo prospetivo observacional numa unidade de cuidados intermédios de um hospital universitário. Foram incluídos e posteriormente comparados os doentes com idade igual ou superior a 75 anos (grupo de estudo) e inferior a 65 anos (grupo controlo) submetidos a VNiPP por FRA. O endpoint primário foi a mortalidade (hospitalar e 30 dias após a alta). Os endpoints secundários foram parâmetros, complicações e taxa de falência de VNPP. Resultados: Foram incluídos um total de 109 doentes. A Mortalidade hospitalar foi significativamente maior no grupo de estudo (22,2 % vs 8,1%, p < 0,01). Contudo, a mortalidade aos 30 dias após alta não foi significativamente diferente (4,1% vs 4,9%, p = 0,37). A duração de uso de VNiPP (6,1 vs 2,2 dias, p < 0,01) e de internamento (14,3 vs 6,2 dias, p = 0,01) foram maiores no grupo de estudo. A falência de VNiPP (22,2% vs 16,1 %, p = 0,09) e taxa de complicações (intolerância 8% vs 6%, p = 0,31; úlceras 4% vs 3%, p = 0,28) foram similares entre os grupos. Conclusão: A FRA tem mau prognóstico nos adultos idosos. A maior taxa de mortalidade foi observada nestes doentes, apesar de similar gravidade e similares taxas de falência e complicação de VNiPP. Notavelmente, a mortalidade fora do hospital foi comparável entre os grupos.

  • Open Access

    Disability and its clinical correlates in pulmonary hypertension measured through the World Health Organization Disability Assessment Schedule 2.0: a prospective, observational study

    by Abílio Reis, Mário Santos, Inês Furtado, Célia Cruz, Pedro Sa-Couto, Alexandra Queirós, Luís Almeida, Nelson Rocha

    Objective: To characterise the degree of disability in pulmonary hypertension (PH) patients based on the World Health Organisation Disability Assessment Schedule 2.0 (WHODAS 2.0). Method: A prospective and observational study of patients with documented PH (N = 46). Patients completed the WHODAS 2.0 questionnaire during a scheduled routine clinical visit, and their demographic and clinical characteristics were retrieved from electronic medical records (EMR). In subsequent visits, selected clinical variables were registered to assess disease progression. Results: WHODAS 2.0 scores were indicative of mild to moderate disability for the domains of mobility (22.0 ± 23.2), life activities (23.7 ± 25.5), and participation in society (17.2 ± 15.9), as well as total WHODAS 2.0 score (15.3 ± 15.2). For the domains of cognition (9.1 ± 14.1), self-care (8.3 ± 14.4), and interpersonal relationships (11.7 ± 15.7), scores were lower. Disability scores were, generally, proportional to the PH severity. The main baseline correlates of disability were World Health Organisation (WHO) functional class, fatigue, dyspnoea, 6-minute walking distance (6MWD), and N-terminal pro b-type natriuretic peptide (NTproBNP). Baseline WHODAS 2.0 scores showed significant associations with disease progression. However, this effect was not transversal to all domains, with only a few domains significantly associated with disease progression variables. Conclusions: This PH population shows mild disability, with higher degree of disability in the domains of mobility and life activities. This study is the first one to assess disability in PH using WHODAS 2.0. Further studies should apply this scale to larger PH populations with suitable representations of more severe PH forms.


  • Association of severe and therapy-refractory systemic lupus erythematosus and neuromyelitis optica: a management challenge

    by Inês Furtado, Guiomar Pinheiro, Ana Campar, Teresa Mendonça

    Systemic lupus erythematosus (SLE) is a multisystemic autoimmune disorder. Neuromyelitis optica (NMO) is an infrequent neuroinflammatory disorder, whose association with SLE remains rare. The authors report the case of an 18-year-old woman, with SLE refractory to multiple immunosuppressive therapies and novel biological agents. Under immunosuppressive therapy, the patient presented with transverse myelitis with contiguous spinal cord lesions and urinary incontinence, having been diagnosed with seropositive NMO, which was also proven to be refractory to common treatments. Partial recovery of the neurological deficits occurred with plasmapheresis, although not averting the brain involvement by NMO that ensued. The patient was listed nationally for allogeneic bone marrow transplant, but, unfortunately, no match was found and the patient died of severe cerebral NMO flare with coma due to brain swelling and consequent respiratory failure. Although the association of SLE and NMO is very rare, early diagnosis is crucial to facilitate initiation of immunosuppressive therapy.


  • Open Access

    Seemingly Harmless Differentiated Thyroid Carcinoma Presenting as Bone Metastasis

    by D. Magalhães, C. Costa, I. Furtado, M. J. Matos, A. P. Santos, H. Duarte, M. Afonso, J. Lobo, I. Torres

    Thyroid carcinoma is the most common endocrine neoplasia. Differentiated thyroid carcinomas (DTCs) represent the majority of cases, which usually follow an indolent clinical course with low mortality rates. The authors describe two cases of well DTC without classic histological poor prognosis features, presenting as extensive and unresectable osteolytic bone metastases. DTCs are considered harmless tumours, due to their benign and silent behaviour. The authors want to underline the importance of clinical awareness during follow-up in cases of DTC, which can be aggressive in presentation and behaviour. Timely identification and diagnosis of these tumours are essential for prompt treatment initiation and improvement of overall survival.

  • Tuberculous osteomyelitis of the wrist presenting as a monoarthritis syndrome

    by Maria Juliana Lopes, Inês Furtado, Mariana Brandão, Fátima Farinha

    Osteoarticular tuberculosis is the third most frequent location of tuberculosis after the lung and lymph nodes, accounting for approximately 10%–20% of all cases of extrapulmonary disease. Tuberculosis of the hand and wrist is the rarest osteoarticular location after the shoulder. The authors report the case of a 50-year-old woman without medical history who was diagnosed with isolated tuberculosis of the wrist presenting as monarthritis. The diagnosis was confirmed by histopathological and microbiological examination. Late stages of osteomyelitis are even rarer without any predisposing factors such as immunosuppression. This case underlines the importance of including tuberculosis in the differential diagnosis of monoarthritic syndromes to prevent delayed initiation of therapy and consequent complications and bone damage.